SCHEMBL5042362

SCHEMBL5042362

COc1ccc(C(OC)C(=O)NCc2ccc(C#N)cc2)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.43
VNN1 O95497 1/20 0.43
PDE5A O76074 1/20 0.42
ALDH1A1 P00352 1/20 0.42
AKR1B1 P15121 1/20 0.41
ACACB O00763 1/20 0.41
PKM P14618 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 1/20 0.40
PPARA Q07869 1/20 0.39
CACNA1G O43497 1/20 0.39
CACNA1B Q00975 1/20 0.39
FLT1 P17948 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
PTGES O14684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5042365 1.00 GSK3B (0.43) GSK3BVNN1PDE5AALDH1A1AKR1B1
SCHEMBL5041986 0.88 GSK3B (0.44) GSK3BVNN1ALDH1A1PKMPOLB
SCHEMBL5041980 0.88 GSK3B (0.44) GSK3BVNN1ALDH1A1PKMPOLB
SCHEMBL5037449 0.87 GSK3B (0.43) GSK3BVNN1ALDH1A1PKMPOLB
SCHEMBL5037450 0.87 GSK3B (0.43) GSK3BVNN1ALDH1A1PKMPOLB
SCHEMBL5047829 0.85 HIF1A (0.44) GSK3BVNN1ALDH1A1PKMPOLB
SCHEMBL5047826 0.85 HIF1A (0.44) GSK3BVNN1ALDH1A1PKMPOLB
SCHEMBL5045056 0.84 PKM (0.50) AKR1B1PKMMAPTTSHRPTGES
SCHEMBL5045059 0.84 PKM (0.50) AKR1B1PKMMAPTTSHRPTGES
SCHEMBL5047370 0.82 PKM (0.47) GSK3BVNN1ALDH1A1PKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 GSK3B 4156/4885VNN1 1831/4885PDE5A 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.